Japan's Chuikyo To Weigh In On New Drug Pricing Program
This article was originally published in PharmAsia News
Executive Summary
An experimental drug pricing policy to shelter selected new drugs from price cuts will be high on the agenda for Japan's reimbursement body, the Central Social Medical Insurance Agency, for the coming year, according to the agency's just-released schedule for hearings and discussions for 2011
You may also be interested in...
Japan 2012 NHI Price Revision Takes Shape, Long-Listed Products See Smaller Cuts Than Expected
Japan's MHLW and Finance Ministry face off on the steps needed to shave reimbursement costs.
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan